Research Article
Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study
Table 1
Patient disposition and baseline characteristics.
| | Parameters | All patients (N = 11) | Neoadjuvant setting (N = 1) | Adjuvant setting (N = 3) | Metastatic setting (N = 7) |
| | Age (years), mean ± SD, range | 46.09 ± 11.46 (19–59) | 48 | 44 ± 10.15 (35–55) | 46.71 ± 13.46 (19–59) | | BSA, kg/m2, mean ± SD | 1.63 ± 0.20 | 1.62 | 1.57 ± 0.18 | 1.66 ± 0.23 | | Gender, n (%) | | Men | 4 (36.4) | 1 (100) | 2 (66.7) | 1 (14.3) | | Women | 7 (63.6) | — | 1 (33.3) | 6 (85.7) | | Cancer stage, n (%) | | II | 3 (27.3) | — | 3 (100) | — | | III | 1 (9.1) | 1 (100) | — | — | | IV | 7 (63.6) | — | — | 7 (100) | | Metastasis site, n (%) | | Lungs | — | — | — | 3 (42.9) | | Lymph node | — | — | — | 2 (18.2) | | Bone | — | — | — | 1 (14.3) | | Brain | — | — | — | 1 (14.3) | | ECOG performance score | | 1 | 4 (36.3) | — | 1 (33.3) | 3 (42.9) | | 2 | 7 (63.7) | 1 (100) | 2 (66.7) | 4 (57.1) | | Comorbid disease, n (%) | | Hypertension | 5 (45.5) | 1 (100) | 1 (33.3) | 3 (42.9) | | Diabetes | 1 (9.1) | — | — | 1 (14.3) | | Hypothyroidism | 1 (9.1) | — | — | 1 (14.3) |
|
|
Abbreviations: BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.
|
